The effectiveness of mRNA vaccines has been confirmed during the COVID-19 pandemic. Now, mRNA platform technology is being applied to the development of "cancer vaccines," extending its potential beyond prevention to treatment.

Our CEO, Mr. Tae-jin Kang, will be contributing a series of five expert articles to the pharmaceutical and biotechnology media outlet "THEBIO," discussing how this technology is being utilized in the development of cancer vaccines, as well as the current trends and status of the technology.

Through this series, we expect readers to gain insights into the present and future of mRNA cancer vaccine technology.

The first article, titled "Novel Prize Winning 'mRNA Vaccine' Technology... Evolves Again," explains the process by which mRNA vaccine technology has evolved into cancer vaccines. For more detailed information, please refer to the link below.